In the news
The latest news and resources from Cerevel Therapeutics.
Press Releases and Featured News
- November 23, 2020Cerevel Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
- November 16, 2020Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights
- November 4, 2020Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
- October 6, 2020Cerevel Therapeutics Announces First Patient Dosed in Phase 2 Trial of darigabat, an Investigational Therapy in Development for the Treatment of Epilepsy
- September 14, 2020Cerevel Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
- July 30, 2020Cerevel Therapeutics and Arya Sciences Acquisition Corp II Announce Business Combination, Creating a Publicly Listed Leader in Neuroscience Drug Development
- July 27, 2020Cerevel Therapeutics and Cyclica Announce Research Collaboration to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in Neuroscience
- July 13, 2020Cerevel Therapeutics Announces the Appointment of Kathleen W. Tregoning as Chief Corporate Affairs Officer
- June 12, 2020Cerevel Therapeutics Chairperson and CEO, Tony Coles, M.D., Participates in BIO Digital Panel on Racial Equality in Biotech
Presentations & Events
- October 1, 2020Presentations at Movement Disorder Society Congress 2020: Analyses of Parkinson’s Disease Medication
- September 16, 2020Morgan Stanley 18th Annual Global Healthcare Conference – Fireside chat with Tony Coles
- August 27, 2020Presentation at 2020 Epilepsy Foundation Pipeline Conference: darigabat: The Journey to REALIZE
- August 10, 2020Conference Call to Discuss Business Combination with Cerevel Therapeutics and Arya Sciences Acquisition Corp. II
- August 10, 2020Cerevel Therapeutics Corporate Presentation
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience disease.
Resources for members of the media are included here.
Press contact firstname.lastname@example.org for more information